David Lewis

Title: Inventor David Lewis: A Pioneer in Sustained-Release Derivatives

Introduction

David Lewis, based in Rockville, MD, is an esteemed inventor who has made significant contributions to the field of pharmaceutical sciences. With one patent to his name, Lewis has developed innovative solutions aimed at enhancing drug delivery and efficacy.

Latest Patents

David Lewis holds a patent for "Sustained-release derivatives of hydroxylated analogs of substituted 1-[2[bis(aryl)methoxy]ethyl]-piperazines and -homopiperazines and their use." This invention focuses on sustained-release derivatives intended for binding to the dopamine transporter, offering potential therapeutic effects against substances such as cocaine and methamphetamine. The pharmaceutical compositions he has created aim to improve the treatment of conditions associated with dopamine reuptake and release.

Career Highlights

Lewis is affiliated with the United States of America as represented by the Secretary of the Department of Health and Human Services. His contributions to research and innovation in pharmacology reflect a commitment to addressing pressing medical challenges through enhanced drug formulations.

Collaborations

Throughout his career, David Lewis has collaborated with notable colleagues, including Richard B. Rothman and Kenner C. Rice. These partnerships have played an instrumental role in advancing his research and expanding the applications of his inventions in the pharmaceutical industry.

Conclusion

David Lewis's work exemplifies the spirit of innovation that drives progress in medicine. With his impactful patent on sustained-release drug derivatives, he is paving the way for new therapeutic strategies that could change the lives of many individuals. His dedication to research continues to inspire collaboration and advancement in the field.